Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Neurology indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

REM sleep behaviour disorder

Neurology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Overview

Recognise dream-enactment behaviour, confirm REM sleep without atonia, prevent injury, exclude mimics and medicines, and provide proportionate counselling and follow-up for associated synucleinopathy risk.

Normal REM sleep combines vivid dreaming with active inhibition of most skeletal muscle. In RBD that atonia is incomplete, allowing dream content to be enacted. Behaviours usually occur in the second half of the night when REM is more abundant and can be dramatic, but subtle hand movements, talking or repeated jerks also occur. A witness or home video can clarify timing, eyes, responsiveness, breathing and the relationship between movement and dream recall, while maintaining privacy and safety.

RBD may accompany alpha-synuclein neurodegeneration, narcolepsy, structural brainstem disease or medicine exposure. A neurological review should therefore look for bradykinesia, rigidity, tremor, gait change, cognitive fluctuation, visual hallucinations, hyposmia, constipation, erectile or urinary dysfunction and orthostatic hypotension. These symptoms are clinical clues rather than a mandate for unvalidated screening biomarkers, and most patients benefit more from longitudinal examination than repeated low-yield imaging.

Video polysomnography confirms REM sleep without atonia and may capture vocal or motor behaviour while identifying apnoea, periodic movements and epileptiform activity. Treatment begins with injury prevention and management of contributors such as sleep apnoea. Medicines are off-label or specialist-led in many UK settings. The aim is fewer dangerous behaviours with preserved daytime alertness, cognition and balance, not abolition of every minor vocalisation at the price of falls or respiratory harm.

Key points

  • REM sleep behaviour disorder causes vocalisation and complex movement that corresponds to vivid dreams because the normal skeletal-muscle atonia of REM sleep is lost.
  • Events are often reported by a bed partner and may include shouting, punching, kicking, leaping or falling from bed, with rapid alertness and dream recall when awakened.
  • Diagnosis requires a compatible history plus video polysomnographic evidence of REM sleep without atonia, with another sleep, neurological or substance cause excluded.
  • Obstructive sleep apnoea can provoke vigorous arousals that mimic RBD, while nocturnal epilepsy, NREM parasomnia, periodic movements, PTSD and nocturnal panic need different management.
  • Ask about antidepressants, beta blockers, alcohol and sedative withdrawal, but do not stop an antidepressant abruptly; weigh psychiatric stability and symptom timing with the prescriber.
  • Immediate management is environmental safety: remove weapons and sharp furniture, pad the floor, lower or separate the bed when necessary and protect the bed partner without restraining the sleeper.
  • Clonazepam and melatonin are commonly used by specialists, but evidence is limited and selection must account for falls, cognition, obstructive sleep apnoea, respiratory depression and daytime sedation.

Aetiology

01

Isolated prodromal synucleinopathy

RBD can precede Parkinson disease, dementia with Lewy bodies or multiple-system atrophy by years, although individual timing remains uncertain.

02

Established neurodegeneration

Brainstem synuclein disease commonly causes RBD alongside parkinsonism, cognitive, autonomic and other sleep features during progression.

03

Medicine and substance effects

Antidepressants, beta blockers, alcohol and sedative withdrawal can provoke or reveal dream enactment, requiring cautious chronology rather than abrupt discontinuation.

04

Narcolepsy and brainstem disease

Narcolepsy, structural lesions and inflammatory brainstem disease can disrupt REM control through mechanisms distinct from later-life synucleinopathy.

Pathophysiology

  1. 1
    REM-atonia circuit failure

    Brainstem networks that normally inhibit spinal motor neurons during REM sleep no longer suppress skeletal muscle activity reliably.

  2. 2
    Motor release during dreaming

    Vivid dream content is accompanied by vocalisation and complex limb or body movement while REM physiology continues.

  3. 3
    Abrupt awakening

    The person often becomes alert quickly and recalls a corresponding dream, distinguishing the event from many confused NREM arousals.

Clinical features and red flags

Dream-congruent enactment

The person appears to defend, chase or escape in a vivid dream and can often describe matching content immediately after being awakened.

Later-night predominance

Episodes commonly cluster in the second half of sleep when REM periods lengthen, unlike many disorders of arousal from deep NREM sleep.

Rapid orientation

Awakening from an RBD event usually produces alertness without prolonged confusion, although injury, sedatives and neurodegeneration can alter the picture.

NREM parasomnia contrast

Sleepwalking and night terrors often arise in the first third of the night, with reduced responsiveness, limited dream recall and confusion after interruption.

Synucleinopathy clues

Hyposmia, constipation, orthostatic symptoms, subtle bradykinesia, cognitive fluctuation or visual hallucinations support broader neurological follow-up.

Red flags requiring action

  • Strangulation, weapon use, major falls, head injury or risk to a bed partner requires immediate separation and environmental safety before diagnostic testing is complete.
  • Events with prolonged unresponsiveness, stereotyped tonic posturing, tongue injury or post-ictal confusion require assessment for nocturnal epilepsy.
  • Loud snoring, witnessed apnoea, cyanosis or marked daytime sleepiness suggests untreated obstructive sleep apnoea and increases sedative treatment risk.

Investigations

  1. 01
    Bed-partner history and event videoFirst step
    Why
    Characterise timing, vocalisation, movement, dream recall, responsiveness, breathing and injury from a witness perspective.
    Interpretation and limitations
    Video can support triage but does not show sleep stage or muscle tone and cannot replace formal polysomnography for diagnosis.
  2. 02
    Video polysomnography
    Why
    Demonstrate REM sleep without atonia, capture dream enactment and identify respiratory, movement or seizure mimics.
    Interpretation and limitations
    A quiet laboratory night can still show abnormal REM muscle activity; scoring and clinical correlation should follow an experienced sleep service.
  3. 03
    Respiratory sleep assessment
    Why
    Diagnose obstructive sleep apnoea that can mimic RBD or make sedative therapy hazardous.
    Interpretation and limitations
    Treat significant apnoea and then reassess behaviours; true RBD and apnoea can coexist rather than being mutually exclusive.
  4. 04
    Neurological examination
    Why
    Identify parkinsonism, eye-movement change, neuropathy, cerebellar disease, cognition or autonomic features suggesting secondary RBD.
    Interpretation and limitations
    A normal examination is common in isolated RBD and does not eliminate future risk; document a baseline for longitudinal comparison.
  5. 05

Differential diagnosis

01

Obstructive sleep apnoea

Respiratory events can provoke vigorous movements at arousal; polysomnography shows apnoea-linked behaviour without true REM sleep without atonia.

02

Nocturnal epilepsy

Brief highly stereotyped events, clustering and ictal EEG or semiology support seizures rather than dream enactment.

03

NREM parasomnia

Sleepwalking and confusional arousals usually arise from deep NREM sleep with poor dream recall and incomplete alertness.

04

PTSD or nocturnal panic

Trauma-linked nightmares and autonomic arousal may cause movement but do not by themselves establish physiological loss of REM atonia.

Additional chapter-specific clues

Obstructive apnoea mimic

Choking, snoring and vigorous movement at respiratory arousals can resemble dream enactment and may resolve when sleep-disordered breathing is treated.

Management

01SAFEInjury prevention tonightFirst stepDream enactment has caused or nearly caused harm before specialist diagnosis.+
  1. 1Remove weapons, glass, sharp furniture and unstable bedside objects and pad nearby surfaces or place a mattress low to the floor.
  2. 2Use separate sleeping temporarily when the partner is at risk and avoid physical restraint, which can intensify injury during an event.
  3. 3Reduce sleep deprivation and alcohol and review sedatives, while not stopping antidepressants or dependence-forming medicines abruptly.
  4. 4Arrange sleep-service assessment and seek urgent care for head injury, breathing compromise or episodes suggesting seizure.
02CONFIRMSuspected RBDA witness describes recurrent vocal or motor enactment of vivid dreams.+
  1. 1Establish night timing, dream recall, awareness, stereotypy, injury, snoring, apnoea, daytime sleepiness and medicine or substance exposure.

Complications

01

Injury to patient or bed partner

Punching, kicking, leaping and falls cause bruises, fractures, head injury and relationship fear during violent episodes.

02

Later neurodegenerative disease

Isolated RBD carries substantial future synucleinopathy risk, requiring proportionate counselling without deterministic prediction over long-term follow-up.

03

Sleep and relationship disruption

Repeated violent episodes fragment sleep, lead to separate sleeping arrangements and cause anxiety for both partners.

04

Treatment-related harm

Sedating medicines can worsen falls, cognition, sleep apnoea and daytime driving safety, particularly in older adults.

Monitoring and follow-up

  • Record event and injury frequency, night timing, dream recall and bed-partner safety before and after each intervention.
  • Review morning sedation, falls, cognition, respiratory symptoms and alcohol or opioid exposure after melatonin or clonazepam changes.
  • Ensure obstructive sleep apnoea treatment is used effectively and repeat respiratory assessment when symptoms or weight change.
  • Perform periodic neurological review for bradykinesia, rigidity, tremor, gait, smell, cognition, hallucinations and autonomic symptoms when the patient wants surveillance.
  • Assess daytime sleepiness and driving risk separately because RBD events themselves do not quantify alertness at the wheel.
  • Review the ongoing need for bedroom separation and safety modification even when medicine appears effective.
  • Reassess the diagnosis if events become highly stereotyped, occur only from early-night deep sleep or develop prolonged impaired awareness.

Special situations

Dream recall is a clue

Immediate recall of a vivid defensive dream matching observed movement supports REM enactment but is not sufficiently specific to replace polysomnography.

Apnoea can act violently

A respiratory arousal can produce thrashing and shouting, creating pseudo-RBD that improves when airway obstruction is treated.

Quiet study nights still count

Video may not capture a dramatic attack, yet abnormal tonic or phasic muscle activity during REM can establish the physiological disorder.

Association is not a countdown

Isolated RBD carries substantial group-level synucleinopathy risk, but an individual cannot be given a precise diagnosis date from that association.

DLB clue may precede dementia

Confirmed REM sleep behaviour disorder can appear years before cognitive fluctuation, visual hallucinations or parkinsonism in dementia with Lewy bodies.

Safety outlives medication

Treatment reduces frequency rather than guaranteeing abolition, so a safer sleep environment remains part of long-term care.

Common pitfalls

  1. 01

    Do not diagnose RBD from one restless night without dream-enactment history and polysomnographic confirmation.

  2. 02

    Do not ignore obstructive sleep apnoea, which can mimic RBD and increases clonazepam risk.

  3. 03

    Do not stop antidepressants abruptly or sacrifice psychiatric stability without shared specialist review.

  4. 04

    Do not prescribe clonazepam reflexively to an older person with falls, cognitive impairment or untreated apnoea.

  5. 05

    Do not promise that melatonin is risk-free or assume over-the-counter formulations provide consistent dose and quality.

  6. 06

    Do not tell every patient that Parkinson disease is inevitable or order unvalidated prediction tests routinely.

  7. 07

    Do not rely on medicine alone while weapons, hard furniture or a vulnerable bed partner remain exposed.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
NeurologyOriginal SBA

Confirming dream enactment

A 66-year-old repeatedly punches and shouts during vivid defensive dreams, mostly late at night, and is quickly oriented when awakened. What investigation is most appropriate to confirm the suspected disorder?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Neurology topics →
Sources and review status7 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG97 dementia recommendationsREM sleep behaviour disorder as a Lewy body dementia feature and diagnostic context.
  • NICE NG71 Parkinson disease recommendationsSleep disturbance and specialist neurological review in Parkinson disease.
  • BNF clonazepam monographUK dosing, respiratory, falls and dependence cautions.
  • BNF melatonin monographUK formulations, adverse effects and interactions.
  • DVLA neurological fitness guidanceDriving standards when neurological disease or daytime sleepiness affects safety.
  • International RBD diagnostic proceduresPrimary expert consensus on video-polysomnographic diagnosis.
  • AASM clinical practice guideline for RBDPrimary guideline supporting injury prevention and treatment choices; applied with UK formulary governance.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Idiopathic or isolated RBD is strongly associated with later Parkinson disease, dementia with Lewy bodies or multiple-system atrophy, but individual timing is uncertain and counselling should avoid deterministic prediction.
  • Rapid cognitive decline, recurrent visual hallucinations, parkinsonism or severe autonomic failure requires expedited neurological assessment for established neurodegenerative disease.
  • Daytime falls, confusion or respiratory worsening after clonazepam or another sedative requires prompt dose and treatment review.
    • Cognitive and autonomic assessment
    Why
    Investigate reported cognitive fluctuation, hallucination, orthostatic, bowel, urinary or sexual symptoms.
    Interpretation and limitations
    Use validated testing and lying-to-standing pressure when indicated, while recognising that constipation or dizziness has many non-neurological causes.
  • 06
    EEG or extended seizure monitoring
    Why
    Evaluate stereotyped brief episodes or impaired awareness when nocturnal frontal or temporal epilepsy remains possible.
    Interpretation and limitations
    A routine normal EEG does not exclude nocturnal epilepsy; capture of a typical event may be necessary when history remains ambiguous.
  • 07
    MRI brain
    Why
    Assess a structural brainstem or neurological cause when onset is unusual, focal signs occur or disease progresses rapidly.
    Interpretation and limitations
    Routine MRI is not required solely to predict Parkinson disease in otherwise typical isolated RBD and should answer a defined clinical question.
  • 2Perform neurological and cognitive screening and look for parkinsonian, autonomic, hallucination or narcolepsy features.
  • 3Refer for video polysomnography to demonstrate REM without atonia and evaluate apnoea, NREM parasomnia and nocturnal epilepsy.
  • 4EscalationClassify isolated, medication-associated or secondary RBD and treat coexisting sleep apnoea before escalating sedating treatment.
    • 03TREATPersistent dangerous behaviourEnvironmental measures and treatment of contributors do not adequately prevent injury.+
    1. 1Define the target behaviour and baseline frequency and review falls, cognition, apnoea, breathing, alcohol, opioids and other sedatives.
    2. 2Select melatonin or clonazepam with a sleep or neurology specialist, using a low dose and explaining limited comparative evidence.
    3. 3Reassess dream enactment, injuries, partner safety, alertness, balance and breathing soon after initiation or dose change.
    4. 4Stop or adjust ineffective or harmful treatment and maintain environmental protection even when episodes improve.
    04FOLLOWIsolated RBD surveillanceRBD is confirmed without established Parkinson disease, dementia with Lewy bodies or multiple-system atrophy.+
    1. 1Explain the association with future synucleinopathy in balanced language, including that timing and individual outcome cannot be predicted precisely.
    2. 2Agree whether the person wants periodic neurological, cognitive and autonomic review and identify symptoms that should prompt earlier assessment.
    3. 3Support advance planning and research discussion without ordering unvalidated biomarkers as routine clinical prediction tools.
    4. 4Continue sleep, safety and medicine review independently of whether neurodegenerative signs emerge.
    Key medicines and prescribing safety3 treatments · regimens, roles and cautions+
    May reduce dream enactment with less respiratory and balance impairment than benzodiazepine treatment in some patients.

    Modified-release melatonin

    Use an off-label or licensed-formulation dose selected by the sleep specialist, commonly starting low in the evening and titrating gradually to nocturnal behaviour and morning alertness.

    Product bioavailability varies, evidence is limited, and daytime drowsiness, headache and interactions can occur; prescribe a consistent regulated preparation.

    Can suppress injurious dream-enactment behaviour in selected patients with confirmed RBD.

    Clonazepam

    A specialist may start 0.25–0.5 mg orally at bedtime and cautiously titrate only if dangerous behaviours persist and tolerability remains acceptable.

    Falls, cognitive impairment, dependence, daytime sedation and worsening obstructive sleep apnoea or respiratory disease are important; avoid alcohol and opioids and do not stop abruptly.

    May reduce medication-associated dream enactment when psychiatric stability allows a safe change.

    Antidepressant review

    If onset follows an SSRI, SNRI or tricyclic, any reduction or switch should use the medicine-specific gradual plan agreed with psychiatry or the original prescriber.

    Abrupt withdrawal can cause discontinuation symptoms, relapse and REM rebound; persistent RBD after a change may reveal an underlying predisposition rather than a simple adverse effect.

    Authoring stateComplete draft
    Clinical stateAwaiting review
    JurisdictionUnited Kingdom